Engineered Autologous T Cell Therapy, CAR-T
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
20
NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Phase: Phase 1
Role: Collaborator
Start: May 23, 2023
Completion: Apr 1, 2038
Loading map...